Preclinical data of Curis’ HSP 90 inhibitor published (News-Medical-Net)

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.
(more…)

Related items

• Nanotechnology approach may fight problems linked to chemo (Sify News)
• Biomoda applauds Senator for introducing legislative bill for lung cancer screening (News-Medical-Net)
• Green Earth Technologies Awarded GSA Contract Through Ed Maxwell Sales, Inc. (PR Newswire via Yahoo! Finance)
• Rexahn, TheraTarget form nano science research collaboration (PharmaBiz)
• Big Hope for Tiny Particles (Technology Review)

Tags: cancer, cancer therapeutics, cancer treatment, company, Curis, curis inc, drug, heat shock protein, Inc, molecular cancer, nano, nanotech, nanotechnology, preclinical data, Technology

This entry was posted on Friday, December 4th, 2009 at 10:50 pm and is filed under News.